| Autor: |
Martínez-Vélez, Naiara, Garcia-Moure, Marc, Marigil, Miguel, González-Huarriz, Marisol, Puigdelloses, Montse, Gallego Pérez-Larraya, Jaime, Zalacaín, Marta, Marrodán, Lucía, Varela-Guruceaga, Maider, Laspidea, Virginia, Aristu, Jose Javier, Ramos, Luis Isaac, Tejada-Solís, Sonia, Díez-Valle, Ricardo, Jones, Chris, Mackay, Alan, Martínez-Climent, Jose A., García-Barchino, Maria Jose, Raabe, Eric, Monje, Michelle |
| Zdroj: |
Nature Communications; 5/28/2019, Vol. 10 Issue 1, pN.PAG-N.PAG, 1p |
| Abstrakt: |
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032). The oncolytic virus Delta-24-RGD is in clinical trial for adult glioma. Here, the authors show that this virus elicits an immune response in mouse models of pediatric high-grade glioma and diffuse pontine intrinsic glioma, resulting in improved survival. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
